We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery
Product News

Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery

Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery
Product News

Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RapidFire, a robust, in-line solid phase extraction technology enables ultrafast, direct analysis of native compounds for a wide variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec is the first Pharmaceutical Contract Research Organisation in Europe to offer these services. The Evotec facility in Hamburg will be equipped with state-of-the-art technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.

“Evotec is the ideal partner for Agilent Technologies as we expand this industry-leading platform into the European Contract Research market,” said Gustavo Salem, Agilent Vice President and General Manager, Biological Systems Division. “Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard Mass Spectrometry platforms.”

Advertisement